Figure 1.

Statins provide favorable prognostic outcomes in patients with pancreatic cancer and displays the anti-growth effects on pancreatic cancer cells. A. Upper: Kaplan-Meier curve of overall survival (OS) in resected pancreatic cancer patients with and without statin intakes. The median survival of statin users was 45 months while the median survival of non-statin users was 29 months (P = 0.024). Below: Kaplan-Meier curve of recurrence-free survival (RFS) in resected pancreatic cancer patients with and without statin intake. The median relapse-free survival of statin users was 27 months, while that of non-statin users was 14 months (P = 0.049). B. Anti-growth effects on pancreatic cancer cells (MIA PaCa2, PK-8, PANC-1, and AsPC-1) using five types of statins (simvastatin, fuvastatin, atorvastatin, pravastatin, and rosuvastatin) at different concentration (5 μM, 10 μM, and 15 μM). The medium in each well was changed daily. Viable cell numbers were measured at 72 h using a Cell Counting Kit-8 (CCK-8). C. Anti-growth effect of the five types of statins on MIA PaCa2 cells. The medium in each well was changed daily. Viable cell numbers were measured at 24, 48, and 72 h using the Cell Counting Kit-8 (CCK-8).